T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma
-
Published:2022-08
Issue:2
Volume:77
Page:397-409
-
ISSN:0168-8278
-
Container-title:Journal of Hepatology
-
language:en
-
Short-container-title:Journal of Hepatology
Author:
Barsch MaryamORCID, Salié HenrikeORCID, Schlaak Alexandra EmiliaORCID, Zhang Zhen, Hess Moritz, Mayer Lena Sophie, Tauber Catrin, Otto-Mora Patricia, Ohtani Takuya, Nilsson TobiasORCID, Wischer Lara, Winkler Frances, Manne Sasikant, Rech Andrew, Schmitt-Graeff Annette, Bronsert Peter, Hofmann MaikeORCID, Neumann-Haefelin ChristophORCID, Boettler Tobias, Fichtner-Feigl Stefan, van Boemmel Florian, Berg ThomasORCID, Rimassa LorenzaORCID, Di Tommaso LucaORCID, Saeed AnwaarORCID, D’Alessio Antonio, Pinato David J., Bettinger DominikORCID, Binder HaraldORCID, John Wherry E., Schultheiss Michael, Thimme Robert, Bengsch BertramORCID
Reference30 articles.
1. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med,2020 2. IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC);Finn;J Clin Oncol,2021 3. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma;Flecken;Hepatology,2014 4. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features;Sia;Gastroenterology,2017 5. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial;Finn;J Clin Oncol,2020
Cited by
91 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|